معرفی
Dr. Laurent Rigoreau is a researcher at Newcastle University, specializing in the development of kinase inhibitors for cancer therapy. His work focuses on extracellular-related kinase 5 (ERK5) and DNA-dependent protein kinase (DNA-PK) inhibition, with contributions to high-throughput screening, pharmacokinetics, and radiosensitization studies. Collaborations include prominent academics such as Professor Roger Griffin, Professor Nicola Curtin, and Dr. Celine Cano, spanning publications from 2001 to 2019.
Research Interests: Dr. Rigoreau's research centers on biochemistry and pharmacology, targeting DNA repair mechanisms and signal transduction pathways in cancer. He has contributed to the discovery of selective kinase inhibitors and anti-cancer agents, with a focus on radiosensitization and drug development for enhanced therapeutic outcomes.
Key Publications: His work includes novel ERK5 and DNA-PK inhibitors, exploring their roles in cancer progression and treatment. These studies often involve
- structure-activity relationships
- pharmacokinetics
- in vitro and in vivo validation